Medical AIStop a GLP-1, regain the weight? What the trials show.
A common worry: if you stop semaglutide, does the weight come straight back? The trial data say much of it does. Here is what the STEP 1 extension and STEP 4 found, and why obesity medicine treats this as a chronic, relapsing condition.
One of the most common questions about GLP-1 receptor agonists such as semaglutide is also the most practical: what happens if you stop? Do you have to take it forever? The honest answer from the trial data is that, for most people, much of the lost weight returns once the drug is withdrawn. That is not a failure of willpower; it is the expected behavior of a chronic condition once its treatment is removed.
The clearest evidence comes from two semaglutide trials with opposite designs. The STEP 1 extension followed people after the drug was stopped. STEP 4 tested what happens when treatment is continued versus withdrawn. Together they bracket the question.
In the STEP 1 extension, participants regained roughly two-thirds of their lost weight within a year of stopping semaglutide and lifestyle intervention.[1] In STEP 4, continuing the drug maintained and extended the loss while switching to placebo led to regain.[2] The practical implication: for most people, a GLP-1 manages weight rather than cures it.
What STEP 1 showed after stopping
STEP 1 was the pivotal obesity trial of once-weekly semaglutide 2.4 mg. In its extension, treatment and lifestyle intervention were stopped at week 68 and participants were followed for another year. Mean weight loss at week 68 had been 17.3% with semaglutide. After withdrawal, participants regained 11.6 percentage points of that loss by week 120, leaving a net reduction of about 5.6% from baseline.[1] That regain of 11.6 out of 17.3 points is roughly two-thirds of what had been lost. Cardiometabolic improvements (such as blood pressure and lipids) largely tracked the weight back up.[1]
STEP 1 extension, mean changes with semaglutide 2.4 mg. Treatment and lifestyle support were both stopped at week 68.
| Timepoint | Mean weight change from baseline | What it means |
|---|---|---|
| Week 68 (on treatment) | -17.3% | Peak loss while on the drug [1] |
| Week 120 (1 year after stopping) | -5.6% | 11.6 points regained, about two-thirds of the loss [1] |
What STEP 4 showed about continuing
STEP 4 used a withdrawal design. Everyone took semaglutide for a 20-week run-in, then participants were re-randomized to continue the drug or switch to placebo through week 68. Those who continued lost a further 7.9% on average from week 20 onward; those switched to placebo regained 6.9% over the same window.[2] The contrast is the point: continued treatment kept and added to the loss, while stopping reversed a substantial part of it.
Why this is framed as a chronic condition
Obesity-medicine guidance treats obesity as a chronic, relapsing disease driven by biology that does not disappear when weight comes off. GLP-1 receptor agonists act on appetite and energy regulation while they are present in the body; when the drug clears, those signals revert and appetite and weight tend to follow.[1,2] In that framing, needing ongoing therapy is analogous to ongoing treatment for hypertension or type 2 diabetes, not evidence that the treatment did not work.
The weight regain after stopping is the expected behavior of a chronic condition, not a sign the drug failed. The decision is whether continued treatment fits the person.- Section synthesis
At the bedside
Set expectations early: most people who stop will regain a large share of the loss, so the conversation is less "when can I stop" and more "what is the long-term plan." Where cost, tolerability, or pregnancy planning force a pause, anticipate regain and reinforce diet, activity, and follow-up. None of this is a directive to start or stop a medication; it is context for a shared decision with a clinician who knows the individual.
The library is curated. The product is asked.
Whether to continue, taper, or stop a GLP-1 depends on your goals, tolerability, cost, and how your body responds. Ask about your own situation rather than the general rule.
This page is verified against the cited primary sources. It summarizes published trial findings and is not a recommendation to start, continue, or stop any medication. Decisions about therapy belong with your clinician.
Medical AI returns evidence-grounded answers backed by real citations. It is a reference tool, and these terms describe how it should and should not be used.
01 Educational purpose
Medical AI is an information and reference tool intended for educational use only. The answers it returns are not medical advice, diagnosis, or treatment. Always consult a qualified doctor or healthcare professional with any question concerning a medical condition.
02 Professional use
Medical AI is designed for use by practicing clinicians. It is not intended for direct patient use and is not a substitute for professional clinical judgment. Apply your own training and current guidelines to every decision an answer informs.
03 Privacy and data
We do not collect, store, or process personally identifiable patient information (PHI or PII). Do not enter names, dates of birth, medical record numbers, or any other patient identifiers into the composer.
04 Information currency
Medical knowledge evolves rapidly. Citations carry their publication date, so consult the primary source and the most recent clinical guideline before acting on anything material.